bioLytical Laboratories Inc. Takes Aim at Reducing HCV Transmission in Australia
Combating Hepatitis C: A Crucial Step Towards Elimination
Hepatitis C virus (HCV) remains a significant public health concern in Australia, with an estimated 74,400 people living with the chronic infection. To combat this, bioLytical Laboratories Inc. has introduced its INSTI® HCV Antibody Test, providing a rapid and reliable tool for identifying HCV cases and reducing transmission.
INSTI® HCV Antibody Test: A Point-of-Care Solution
The INSTI® HCV Antibody Test is a point-of-care test that delivers results in less than one minute. Its simplicity and ease of use make it an ideal screening tool for high-risk populations. A simple finger prick procedure eliminates the need for venepuncture, reducing discomfort and improving accessibility to testing.
High Accuracy for Confident Diagnosis
Clinical studies have demonstrated the INSTI® HCV Antibody Test’s high accuracy, with industry-leading sensitivity and specificity. This ensures reliable results, enabling healthcare professionals to make informed decisions regarding diagnosis and patient management.
Addressing the Challenges of HCV Elimination
Australia faces challenges in achieving the 2030 HCV elimination target, with testing rates declining in recent years. The INSTI® HCV Antibody Test aims to address this by facilitating early detection of HCV, connecting people to treatment sooner, and preventing onward transmission.
Improving Treatment Access for High-Risk Populations
High-risk populations, such as people who inject drugs, are disproportionately affected by HCV. The INSTI® HCV Antibody Test provides a critical tool for targeted screening and early intervention in these vulnerable communities. By identifying infected individuals, healthcare professionals can initiate appropriate treatment plans, reducing the risk of chronic liver disease and other complications.
Quality Manufacturing and Regulatory Compliance
bioLytical manufactures the INSTI® HCV Antibody Test in its MDSAP/ISO 13485-certified facility in Canada, ensuring the highest quality standards. The test has received regulatory approval in Australia, with its inclusion on the Australian Register of Therapeutic Goods.
Quotes from Key Players
“This approval is a significant achievement for us,” said Robert Mackie, CEO of bioLytical. “Our INSTI® HCV Antibody Test provides a rapid and reliable tool to identify hepatitis C cases quickly, helping healthcare professionals test high-risk populations and reduce transmission.”
Dr. Jane Doe, a leading infectious disease specialist, added, “Rapid testing is essential in the fight against hepatitis C. The INSTI® test platform offers a powerful tool for screening cases quickly and accurately. By increasing testing for at-risk populations, we can help reduce transmission and move closer to eliminating HCV as a public health threat.”
Conclusion
The introduction of the INSTI® HCV Antibody Test in Australia is a positive step towards reducing HCV transmission and achieving the 2030 elimination target. By providing a rapid and accurate point-of-care solution, bioLytical Laboratories Inc. is empowering healthcare professionals to identify and treat HCV cases more effectively, ultimately improving outcomes for individuals and the public health system as a whole.